Alnylam Pharmaceuticals, Inc.
DUAL TARGETING siRNA AGENTS
Last updated:
Abstract:
The invention relates to dual targeting siRNA agents targeting a PCSK9 gene and a second gene, and methods of using dual targeting siRNA agents to inhibit expression of PCSK9 and to treat PCSK9 related disorders, e.g., hyperlipidemia.
Status:
Application
Type:
Utility
Filling date:
13 Aug 2021
Issue date:
7 Jul 2022